Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

Multiple Sclerosis

Volumn 21, Issue 9, 2015, Pages 1159-1171

  Kalincik, Tomas ^a,b   Jokubaitis, Vilija ^a,b   Izquierdo, Guillermo ^c   Duquette, Pierre ^d   Girard, Marc ^d   Grammond, Pierre ^e   Lugaresi, Alessandra ^f   Oreja Guevara, Celia ^g   Bergamaschi, Roberto ^h   Hupperts, Raymond ⁱ   Grandmaison, Francois ^j   Pucci, Eugenio ^k   Van Pesch, Vincent ^l   Boz, Cavit ^m   Iuliano, Gerardo ⁿ   Fernandez Bolanos, Ricardo ^o   Flechter, Shlomo ^p   Spitaleri, Daniele ^q   Cristiano, Edgardo ^r   Verheul, Freek ^s   Lechner Scott, Jeannette ^t   Amato, Maria Pia ^u   Cabrera Gomez, Jose Antonio ^v   Saladino, Maria Laura ^w   Slee, Mark ^x   Moore, Fraser ^y   Gray, Orla ^z   Paine, Mark ^aa   Barnett, Michael ^ab   Havrdova, Eva ^ac   Horakova, Dana ^ac   Spelman, Timothy ^a,b   Trojano, Maria ^ad   Butzkueven, Helmut ^a,b,ae   more..

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^d NOTRE DAME HOSPITAL   (Canada)

^e Hotel Dieu de Levis Hospital   (Canada)

^f UNIVERSITY OF CHIETI   (Italy)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

ⁱ Zuyderland Medical Centre   (Netherlands)

^j HÔPITAL CHARLES LEMOYNE   (Canada)

^k Ospedale di Macerata   (Italy)

^l CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^m KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

ⁿ Ospedali Riuniti di Salerno   (Italy)

^o HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^p ASSAF HAROFEH MEDICAL CENTER   (Israel)

^q S G MOSCATI HOSPITAL   (Italy)

^r HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^s Groene Hart Ziekenhuis   (Netherlands)

^t JOHN HUNTER HOSPITAL   (Australia)

^u UNIVERSITY OF FLORENCE   (Italy)

^v CENTRO INTERNACIONAL DE RESTAURACIÓN NEUROLÓGICA CIREN   (Cuba)

^w INEBA ^*  (Argentina)

^x FLINDERS UNIVERSITY   (Australia)

^y MCGILL UNIVERSITY   (Canada)

^z CRAIGAVON AREA HOSPITAL   (United Kingdom)

^aa ST VINCENT S HOSPITAL   (Australia)

^ab UNIVERSITY OF SYDNEY   (Australia)

^ac CHARLES UNIVERSITY   (Czech Republic)

^ad UNIVERSITY OF BARI   (Italy)

^ae MONASH UNIVERSITY   (Australia)

more..

Author keywords

disability; Multiple sclerosis; patient registry; propensity score; real world date; Relapses; treatment outcomes

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; ALPHA1 INTERFERON; BETA INTERFERON; BETA1 INTERFERON; FINGOLIMOD; MITOXANTRONE; NATALIZUMAB; TERIFLUNOMIDE; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; RELAPSE; RISK REDUCTION; TREATMENT RESPONSE; CEREBROSPINAL FLUID; DISABILITY; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; SCORING SYSTEM; SENSITIVITY ANALYSIS; COMPARATIVE STUDY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; REGISTER; TREATMENT OUTCOME;

GLATIRAMER ACETATE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; REGISTRIES; TREATMENT OUTCOME;

EID: 84985916687     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514559865     Document Type: Article

References (33)

1. OConnor P, Filippi M, Arnason B,. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomised, multicentre study. Lancet Neurol 2009; 8: 889-897.
2. Schwid S, Panitch H,. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther 2007; 29: 2031-2048.
3. Durelli L, Verdun E, Barbero P,. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-1460.
4. Koch Henriksen N, Sorensen PS, Christensen T,. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 2006; 66: 1056-1060.
5. Mikol D, Barkhof F, Chang P,. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008; 7: 903-914.
6. Lublin FD, Cofield SS, Cutter GR,. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 2013; 73: 327-340.
7. Trojano M, Pellegrini F, Paolicelli D,. Observational studies: Propensity score analysis of non-randomized data. Int MS J 2009; 16: 90-97.
8. Rosenbaum PR, Rubin DB,. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984; 79: 516-524.
9. Trojano M, Pellegrini F, Fuiani A,. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007; 61: 300-306.
10. Conway DS, Miller DM, OBrien RG,. Long term benefit of multiple sclerosis treatment: An investigation using a novel data collection technique. Mult Scler 2012; 18: 1617-1624.
11. Shirani A, Zhao Y, Karim ME,. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012; 308: 247-256.
12. Kalincik T, Vivek V, Jokubaitis V,. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain 2013; 136: 3609-3617.
13. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
14. Butzkueven H, Chapman J, Cristiano E,. MSBase: An international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler 2006; 12: 769-774.
15. Polman CH, Reingold SC, Edan G,. Diagnostic criteria for multiple sclerosis: 2005 revisions to the €McDonald Criteria€. Ann Neurol 2005; 58: 840-846.
16. Polman CH, Reingold SC, Banwell B,. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
17. Lublin FD, Reingold SC,. Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-911.
18. Schumacher GA, Beebe G, Kibler RF,. Problems of experimental trials of therapy in multiple sclerosis: Report by the Panel on the Evaluation of Experimental Trials of Therapy in Multiple Sclerosis. Ann N Y Acad Sci 1965; 122: 552-568.
19. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2011.
20. Ho DE, Imai K, King G,. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Polit Anal 2006; 15: 199-236.
21. Imai K, King G, Lau O,. Toward a common framework for statistical analysis and development. J Comput Graph Stat 2008; 17: 892-913.
22. Kalincik T, Spelman T, Trojano M,. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. PLoS One 2013; 8: e63480.
23. Rosenbaum PR,. Observational studies. 2nd ed. New York, NY: Springer-Verlag, 2002.
24. Sekhon J,. Multivariate and propensity score matching software with automated balance optimization: The matching package for R. J Stat Software 2011; 42.
25. Etemadifar M, Janghorbani M, Shaygannejad V,. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand 2006; 113: 283-287.
26. Calabrese M, Bernardi V, Atzori M,. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Mult Scler 2012; 18: 418-424.
27. Gobbi C, Zecca C, Linnebank M,. Swiss analysis of multiple sclerosis: A multicenter, non-interventional, retrospective cohort study of disease-modifying therapies. Eur Neurol 2013; 70: 35-41.
28. Goodin DS, Frohman EM, Hurwitz B,. Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: an evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 68: 977-984.
29. La Mantia L, Di Pietrantonj C, Rovaris M,. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2014; 7: CD009333.
30. Filippini G, Del Giovane C, Vacchi L,. Immunomodulators and immunosuppressants for multiple sclerosis: A network meta-analysis. Cochrane Database Syst Rev 2013; 6: CD008933-CD.
31. Smith B, Carson S, Fu R,. Drug class review: Disease-modifying drugs for multiple sclerosis: final update 1 report [Internet]. (2010,. accessed 12 Oct 2013).
32. Ming K, Rosenbaum PR,. Substantial gains in bias reduction from matching with a variable number of controls. Biometrics 2000; 56: 118-124.
33. Khan O, Rieckmann P, Boyko A,. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol 2013; 73: 705-713.